TW202317215A - Antiviral base material and mask - Google Patents

Abstract

[Problem] To provide an antiviral base material with which the product quality of the antiviral base material can be secured, and a mask. [Means for Resolution] An antiviral base material 20 is a base material having antiviral properties, the antiviral base material 20 including a first base material 21 constructed of a paper material; and an antiviral layer 22 formed by applying a tea leaf extract material extracted from tea leaves on the first base material 21, in which an amount of coating of the tea leaf extract material in the antiviral layer 22 is set to 0.1 g/m ²or more, and the tea leaf extract material includes catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate.

Description

Anti-virus basic materials and masks

The invention relates to an antiviral basic material and a mask.

In the past, a base material comprising a sheet-like body composed of a non-woven fabric coated with catechin; an adhesive layer provided on the surface of the sheet-like body; Surface release sheet (for example, refer to Patent Document 1). reference list patent documents

Patent Document 1: Japanese Utility Model Registration No. 3,227,491

technical problem

Here, in the description of the related art, the sheet-shaped main body is coated with catechin; however, since the details of the coating are unclear, if the coating amount of the catechin is insufficient, it may be difficult for the base material to have the desired resistance. virus properties. Therefore, there is still room for improvement from the viewpoint of securing the product quality of the base material (specifically, product quality related to antiviral properties).

The present invention is invented to solve the problems in the above-mentioned related technologies, and its purpose is to provide an antiviral basic material capable of ensuring the product quality of the antiviral basic material, and a mask. solution to the problem

In order to solve the above problems and achieve the purpose, the antiviral basic material as described in claim 1 is an antiviral basic material with antiviral properties, and the antiviral basic material includes: a first base composed of paper material or fabric material Material: an antiviral layer formed by applying tea extract material extracted from tea leaves on the first base material, wherein the coating amount of the tea extract material in the antiviral layer is more than 0.1 g/m ² .

The antiviral basic material according to claim 2 of the antiviral basic material according to claim 1, wherein the coating amount of the tea extract material in the antiviral layer is 0.2 g/m ² or more.

The antiviral basic material of claim 3 of the antiviral basic material as described in claim 1 or 2, wherein the tea extract material contains catechin, epicatechin, epigallocatechin, epicatechin Gallate, Epigallocatechin Gallate, Theaflavin, Theaflavin-3-O-Gallate, Theaflavin-3'-O-Gallic Acid Esters and theaflavin-3,3'-digallate.

The antiviral basic material of claim 4 of the antiviral basic material as described in claim 1 or 2, wherein the antiviral basic material includes a plurality of second basic materials made of paper materials and/or fabric materials, the plurality of second basic materials The second base materials are not provided with the antiviral layer, the plurality of second base materials are provided in a laminated form, and the first base materials are provided between the second base materials so that the first base materials are not exposed to the outside.

The antiviral basic material according to claim 5 of the antiviral basic material according to claim 4, wherein among the plurality of second basic materials, at least one of the second basic materials located on one side of the stacking direction relative to the first basic material The mesh size of any one is set to be smaller than the mesh size of the second base material located on the other side of the stacking direction with respect to the first base material.

The mask as described in claim 6 comprises a mask body formed from the antiviral basic material as described in claim 1 or 2. Beneficial effects of the present invention

The antiviral basic material as described in Claim 1, since the antiviral basic material includes an antiviral layer formed by applying the tea extract material extracted from tea leaves on the first basic material, and the tea extract in the antiviral layer The coating amount of the material is set to 0.1 g/ ^m2 or more, so that the antiviral base material can have the desired antiviral properties, and the product quality of the antiviral base material (specifically, the product quality of the antiviral properties) can be ensured. .

As the antiviral basic material described in claim 2, since the coating amount of the tea extract material in the antiviral layer is set at 0.2 g/m2 or ^more , the antiviral basic material can have higher antiviral properties, and can further Ensure the product quality of antiviral basic materials.

The antiviral basic material as described in Claim 3, because the tea extract material contains catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin Theaflavin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate and theaflavin-3,3'- Digallate, the antiviral base material 20 can reliably have desired antiviral properties, and the product quality of the antiviral base material can be easily ensured.

As the antiviral base material described in Claim 4, since a plurality of second base materials are arranged in a layered form, and the first base material is arranged between the second base materials, the first base material is not exposed to the outside, which can avoid The exposure of the first base material to the outside can prevent the degradation of the design performance of the anti-virus base material caused by the first base material, and can improve the protective performance of the first base material.

As the antiviral base material described in Claim 5, among the plurality of second base materials, the mesh size of at least any one of the second base materials located on one side of the stacking direction relative to the first base material is set to be smaller than the relative The mesh size of the second base material on the other side of the stacking direction from the first base material. Compared with the case where the sieve sizes of the plurality of second base materials are the same, it is difficult for foreign objects and/or viruses to pass through, so the filtering function can be improved.

As the mask described in claim 6, since the mask includes a mask body formed from the antiviral basic material as described in claim 1 or 2, the product quality of the mask body can be ensured through the product quality of the antiviral basic material, and It can enhance the manufacturability of masks.

Hereinafter, embodiments of the antiviral base material and mask according to the present invention will be described in detail with reference to the accompanying drawings. First, the basic concept of the [I] embodiment will be described, then the specific content of the [II] embodiment will be described, and finally the modified examples of the [III] embodiment will be described. However, the present invention is not intended to be limited by these Examples.

[I] Basic concept of the embodiment: First, the basic concept of the embodiment will be described. The embodiments generally relate to an antiviral base material having antiviral properties, and masks comprising the antiviral base material.

Here, the term "antiviral properties" refers to the property of inactivating viruses.

In addition, "basic material" is a component constituting a product component, and in the embodiments, the base material is described as a component constituting a component of a mask (specifically, a mask body to be described below). However, without being limited thereto, for example, the base material may also be paper products (including, for example, disposable diapers, facial tissue, toilet paper, boxes, wallpaper, and printed paper) and/or fabric products (such as including cloth diapers) other than face masks. , handkerchiefs, towels, clothing and cloth bags).

[II] Specific contents of the embodiment: Next, the specific contents of the embodiment will be described.

(Configuration): First, the mask configuration according to the embodiment will be described.

In the following description, the X direction in Figure 1 is called the left-to-right direction of the mask (based on the observation direction of the wearer not shown in the figure, the -X direction is the right-hand direction of the mask, and the +X direction is the left-hand direction of the mask ), the Y direction in Figure 1 is called the front and rear direction of the mask (+Y direction is the front direction of the mask, -Y direction is the back direction of the mask), and the Z direction in Figure 1 is called the up and down direction of the mask (+Z direction is the upward direction of the mask, and the -Z direction is the downward direction of the mask).

The mask 1 is used to cover the mouth and nose of the wearer. As shown in FIG.

(Configuration—Mask Main Body) First, the configuration of the mask main body 10 will be described.

The mask main body 10 is the basic structure of the mask 1. When the wearer wears the mask 1 (hereinafter referred to as "wearing state"), the mask main body 10 is installed in a position that can roughly cover the part extending from the nose to the chin of the wearer. In addition, this mouth mask main body 10 is formed by the antiviral base material 20 with antiviral properties, specifically, as shown in Figure 1, the mask main body 10 comprises a first base material 21, an antiviral layer 22, an outside second base material 23 , the inner second base material 24 and the middle second base material 25 .

Incidentally, the above "outer second base material 23", "inner second base material 24" and "middle second base material 25" correspond to "a plurality of second base materials" in the claims. In addition, in the following description, between the faces of the mask main body 10 (specifically, the first base material 21, the outer second base material 23, the inner second base material 24, and the middle second base material 25), the The surface 11 on the wearer's skin surface side is called "mask inner surface 11", and the surface 12 on the opposite side to the wearer's skin surface side is called "mask outside surface 12".

(Structure-Mask Main Body-First Base Material) The first base material 21 is a part of the basic structure of the mask main body 10, and as shown in FIGS. 1 and 2, is formed in a substantially sheet-like shape.

The specific shape and size of the first base material 21 are arbitrary; however, according to the embodiment, the shape and size are set as follows.

That is, the front shape of the first base material 21 is set to be substantially quadrangular (specifically, substantially rectangular). However, it is not limited thereto, and for example, the front shape may be approximately square, approximately trapezoidal, or approximately elliptical.

In addition, the length of the left-right direction of the first base material 21 is set to be approximately the same as the length of the mask main body 10 in the left-right direction, for example, the length can be set to approximately from 160 mm to 190 mm. However, it is not limited thereto, for example, the length of the left-right direction of the first base material 21 may be set to be shorter than the length of the mask main body 10 in the left-right direction.

In addition, the length of the up-down direction of the first base material 21 is set to be substantially the same as the length of the up-down direction of the mask main body 10, for example, the length can also be set to about from 80 mm to 110 mm. However, it is not limited to this, For example, the length of the up-down direction of the 1st base material 21 can be set shorter than the length of the up-down direction of the mask main body 10.

In addition, the thickness of the first base material 21 is set to a thickness having desired durability, for example, the thickness may be set to about 0.03 mm to 0.5 mm.

In addition, the material of the first base material 21 is arbitrary; however, according to an embodiment, the first base material 21 is composed of a paper material, specifically, the first base material 21 is made of paper with a basis weight of about 14 g/m ² . It is composed of the known paper material of the mask. However, it is not limited thereto. For example, the first base material 21 can also be made of paper materials other than paper materials for masks (examples include tea scented paper, which will be confirmed in the test results described below to help antiviral properties (specifically For paper materials, tea fragrance paper containing more than 20% tea residue) or mask fabric materials (examples include woven fabric materials, non-woven fabric materials and knitted fabric materials).

(Structure-Mask Main Body-Antiviral Layer) Returning to FIG. 1 , the antiviral layer 22 is a layer that exhibits the antiviral properties of the mask main body 10 . The antiviral layer 22 is formed by applying the tea extract material on the first base material 21. Specifically, as shown in FIGS. 1 and 2, the antiviral layer 22 is formed by applying the tea extract material approximately The whole of the first base material 21 to be impregnated is then formed by drying the tea extract material.

In addition, the specific configuration of the antiviral layer 22 is arbitrary; however, according to the embodiment, it is configured such that the coating amount of the tea extract material in the antiviral layer 22 is 0.1 g/ ^m2 or more.

Specifically, it was configured such that the above coating amount was 0.2 g/m ² from the viewpoint of securing higher antiviral properties, based on test results to be described below. However, not limited thereto, for example, it may be configured so that the above coating amount exceeds 0.2 g/m ² , or it may be configured such that the coating amount is 0.4 g/m ² , for example.

Incidentally, when the coating amount is more than 0.4 g/m ² , it is difficult to apply the tea leaf extract material on the first base material 21 and thus it is difficult to form the antiviral layer 22 on the first base material 21 . Based on this, the upper limit of the above coating amount is set to about 0.4 g/m ² in Examples.

(Structure-mask main body-antiviral layer-tea extract material) Here, the tea extract material is a material extracted from tea leaves (such as green tea leaves and black tea leaves).

The specific configuration of this tea extract material is arbitrary; however, according to the embodiment, from the viewpoint of ensuring the product quality of the mask body 10 (specifically, product quality related to antiviral properties), the tea extract material contains Theanine, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O - gallate, theaflavin-3'-O-gallate and theaflavin-3,3'-digallate. However, it is not limited to these, for example, the tea leaf extract material may contain polyphenols other than these (examples include gallocatechin and gallocatechin gallate).

In addition, when the coating amount of the tea extract material is 0.2 g/ ^m2 , catechin, epicatechin, epigallocatechin, epicatechin gallo Ester, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate and tea The coating amount of the component of flavin-3,3′-digallate is arbitrary; however, according to the embodiment, the coating amount is set to about 0.1 g/m ² . However, it is not limited thereto, for example, the coating amount may be set to be less than 0.1 g/m ² , or may be set to be more than 0.1 g/m ² .

Due to such an antiviral layer 22, the desired antiviral properties of the mask main body 10 can be reliably exhibited. In addition, since the antiviral layer 22 can be made of tea extract material, the antiviral layer 22 can be simply constructed, and at the same time, because the antiviral layer 22 can be formed by using, for example, used tea leaves, the present invention can improve the antiviral layer 22. While improving manufacturability (specifically, reducing manufacturing costs, etc.), it facilitates the reuse of tea leaves.

(Construction-mask main body-outside second base material) Return to Fig. 1, the outside second base material 23 is another part of the basic structure of mask main body 10, is not provided with the base material (second base material) of antiviral layer 22. The outer second base material 23 is formed into a substantially sheet-like body, and as shown in FIG. 1 , the outer second base material 23 is provided on the outer side of the first base material 21 (the front side in FIG. 1( b )).

In addition, the specific shape and size of the outer second base material 23 are arbitrary; however, according to the embodiment, the shape and size are set as follows.

That is, the front shape of the outer second base material 23 is set to be substantially quadrilateral (specifically, substantially rectangular). However, it is not limited thereto, but the frontal shape may be set to, for example, approximately square, approximately trapezoidal, or approximately elliptical.

In addition, the length of the left-right direction of the outer second base material 23 is set to be approximately the same as the length of the mask body 10 in the left-right direction, for example, the length can be set to approximately from 120 mm to 190 mm.

In addition, the length of the up-down direction of the outer second base material 23 is set to be approximately the same as the length of the up-down direction of the mask main body 10, for example, the length can be set to approximately from 80 mm to 110 mm.

In addition, the thickness of the outer second base material 23 is set to have a desired durability, for example, the thickness may be set from about 0.1 mm to 0.7 mm.

In addition, the material of the outer second base material 23 is arbitrary; however, according to an embodiment, the outer second base material 23 is composed of a fabric material, specifically, the material is made of fabric having a basis weight of about 25 g/m ² for The mask is made of non-woven materials (for example, spun-bonded non-woven materials). However, it is not limited thereto. For example, the outer second base material 23 may also be made of fabric materials other than non-woven fabrics for masks (examples include woven fabric materials and knitted fabric materials) or paper materials for masks.

(Structure-mask main body-inner second base material) The inner second base material 24 is another part of the basic structure of the mask main body 10, and is a base material (second base material) without the antiviral layer 22. As shown in FIG. 1( b ), the inner second base material 24 is formed into a substantially sheet-like body, and is provided on the inner side of the first base material 21 (the rear side in FIG. 1( b )).

In addition, the specific shape and size of the inner second base material 24 are arbitrary; however, according to the embodiment, the shape and size are set as follows.

That is, the front shape of the inner second base material 24 is set to be substantially quadrilateral (specifically, substantially rectangular). However, it is not limited thereto, and for example, the front shape may be set to be approximately square, approximately trapezoidal, or approximately elliptical.

In addition, the length of the left-right direction of the inner second base material 24 is set to be approximately the same as the length of the mask main body 10 in the left-right direction, for example, the length can be set to approximately from 160 mm to 190 mm. However, it is not limited thereto, and for example, the length in the left-right direction of the inner second base material 24 may be set to be shorter than the length in the left-right direction of the mask main body 10 .

In addition, the length of the up-down direction of the inner second base material 24 is set to be approximately the same as the length of the up-down direction of the mask main body 10, for example, the length can be set to be approximately from 80 mm to 110 mm. However, it is not limited thereto, for example, the length of the vertical direction of the inner second base material 24 can be set to be shorter than the length of the vertical direction of the mask main body 10 .

In addition, the thickness of the inner second base material 24 is set to a thickness having desired durability, for example, the thickness may be set to about 0.1 mm to 0.7 mm.

In addition, the material of the inner second base material 24 is arbitrary; however, according to an embodiment, the inner second base material 24 is composed of a fabric material, specifically, the material is made of fabric having a basis weight of about 25 g/m ² for The mask is made of non-woven materials (for example, spun-bonded non-woven materials). However, it is not limited thereto. For example, the inner second base material 24 may also be made of fabric materials other than non-woven fabrics for masks (examples include woven fabric materials and knitted fabric materials) or paper materials for masks.

(Structure-mask main body-intermediate second base material) The intermediate second base material 25 is another part of the basic structure of the mask main body 10, and is a base material (second base material) that does not have an antiviral layer 22. The intermediate second base material 25 is formed into a substantially sheet-like body, and the intermediate second base material 25 is provided between the first base material 21 and the inner second base material 24 as shown in FIG. 1( b ).

In addition, the specific shape and size of the intermediate second base material 25 are arbitrary; however, according to the embodiment, the shape and size are set as follows.

That is, the front shape of the intermediate second base material 25 is set to be substantially quadrilateral (specifically, substantially rectangular). However, it is not limited thereto, for example, the front shape may be set to be substantially square, substantially trapezoidal, or substantially elliptical.

In addition, the length in the left-right direction of the middle second base material 25 is set to be approximately the same as the length in the left-right direction of the mask main body 10, for example, the length can be set to approximately from 160 mm to 190 mm. However, it is not limited thereto, and for example, the length in the left-right direction of the middle second base material 25 may be set to be shorter than the length in the left-right direction of the mask main body 10 .

In addition, the length of the up-down direction of the middle second base material 25 is set to be substantially the same as the length of the up-down direction of the mask main body 10, for example, the length can be set to about from 80 mm to 110 mm. However, it is not limited thereto, for example, the length of the vertical direction of the middle second base material 25 may be set to be shorter than the length of the vertical direction of the mask main body 10 .

In addition, the thickness of the intermediate second base material 25 is set to have a desired durability, for example, the thickness may be set to be about 0.1 mm to 0.7 mm.

In addition, the material of the intermediate second base material 25 is arbitrary; however, according to an embodiment, the intermediate second base material 25 is composed of a fabric material, specifically, the material is made of fabric having a basis weight of about 25 g/m ² for The mask is made of non-woven material. For example, since the intermediate second base material 25 is composed of an electrostatically treated (eg, corona treated) meltblown material having a basis weight of about 25 g/m ² , viruses that have passed through the first base material 21 can be intermediated. The second base material 25 restricts the anti-virus properties provided by the first base material 21 to act on the restricted viruses. However, it is not limited thereto. For example, the middle second base material 25 may also be made of fabric materials other than non-woven fabrics for masks (examples include woven fabric materials and knitted fabric materials) or paper materials.

(Configuration—Mask Main Body—Other Configurations) The specific configuration of the mask main body 10 is arbitrary; however, according to the embodiment, the mask main body 10 is configured as follows.

That is, first, a plurality of second base materials (specifically, the outer second base material 23, the inner second base material 24, and the middle second base material 25) are arranged in a stacked form, and the first base material 21 is arranged on the Between the second base materials, the first base material 21 is not exposed to the outside.

Specifically, as shown in FIG. 1( b ), the outer second base material 23 , the inner second base material 24 , and the middle second base material 25 are arranged in a stacked form substantially along the front-rear direction. In addition, the first base material 21 is arranged between the outer second base material 23 and the middle second base material 25, and the first base material 21 is arranged such that the entire front surface of the first base material 21 is covered by the outer second base material 23. At the same time, the entire back surface of the first base material 21 is covered by the inner second base material 24 and/or the middle second base material 25 . Then, the outer second base material 23 and the middle second base material 25 are connected to each other through ultrasonic bonding, thermal bonding, adhesive (such as hot melt adhesive), etc. Ultrasonic bonding, thermal bonding, adhesives (such as hot melt glue), etc. are connected to each other.

Due to such a configuration, the first base material 21 can be prevented from being exposed to the outside, and the design performance of the mask main body 10 (antiviral base material 20 ) can be prevented from being deteriorated by the first base material 21 .

In addition, among the plurality of second base materials, the mesh size of at least any one of the second base materials located on one side of the stacking direction relative to the first base material 21 is set to be smaller than that of the second base material located on the other side of the stacking direction relative to the first base material 21 . The mesh size of the second base material on the side.

Specifically, the mesh size of at least any one of the inner second base material 24 and the middle second base material 25 on the rear side of the first base material 21 is set to be smaller than that of the outer second base material 21 located on the front side of the first base material 21. The mesh size of the material 23. For example, the mesh size of the middle second base material 25 can be set to be less than 10 μm, and the mesh size of the outer second base material 23 and inner second base material 24 can be set to be more than 50 μm.

Due to such a structure, foreign matter and/or viruses are difficult to pass through compared with the case where the mesh sizes of the plurality of second base materials are the same, so the filtering function of the mask main body 10 can be improved. In particular, since the mesh size of the plurality of second base materials is set to the above-mentioned size, the structure can be applied to the mask main body 10 for surgical masks.

Incidentally, the mesh size of the first base material 21 is arbitrary; however, according to the embodiment, the mesh size of the first base material 21 is set to be the same as the mesh size of the outer second base material 23 and the middle second base material. Sizes between the mesh size of 25, for example the mesh size can be set from about 20 μm to 30 μm. However, it is not limited thereto, for example, the mesh size of the first base material 21 may be set to be the same size as the mesh size of the outer second base material 23 or the mesh size of the middle second base material 25 .

Such a mask main body 10 (antiviral base material 20 ) can exert desired antiviral properties and ensure the product quality of the mask main body 10 .

(Configuration - Wrinkled Portion) Next, the configuration of the wrinkled section 30 will be described.

The folds 30 are used to three-dimensionally constitute the mask main body 10 so that the mask main body 10 fits on the wearer's face. The folded portion 30 is a part of the mask body 10 (specifically, the first base material 21, the outer second base material 23, the inner second base material 24, and the middle second base material 25) formed in a longitudinal crease shape. , as shown in FIG. 1 , a plurality of folds 30 are arranged in parallel along the up-down direction, and the folds 30 are spaced apart from each other in the mask main body 10 .

(Configuration—Nose Pad Portion) Next, the configuration of the nose pad portion 40 will be described.

The nose pad 40 is used to fit the mask main body 10 on the wearer's nose. The nose pad 40 is, for example, formed by using a known long nose pad for a mask (for example, a nose pad made of polyolefin and iron). As shown in FIG. The length direction of the nose pad part 40 is generally arranged along the left-right direction, and is fixed on the outer second base material 23 through ultrasonic bonding, thermal bonding, adhesive (such as hot-melt adhesive) and the like.

(Configuration—Ear Side Attachment and Detachment Portion) Next, the configuration of the ear side attachment and detachment portion 50 will be described.

The ear side loading and unloading part 50 is used to install the ear side loading and unloading parts on the wearer's ear freely with the mask main body 10. As shown in Figure 1, the ear side loading and unloading part 50 includes the first ear side loading and unloading part 51 and the second Detachable part 52 on the ear side.

(Structure-Ear Side Detachable Part-First Ear Side Detachable Part) The first ear side detachable part 51 is for detachably attaching the mask main body 10 to the wearer's right ear. The first ear-side detachable part 51 is made of, for example, a known wire for ear hooks (examples include a polyolefin-made substantially loop-shaped wire with a length that can be hung on the right ear) and is provided at the right end of the mask main body 10 . Specifically, as shown in FIG. 1 , one end of the first ear side mounting and dismounting portion 51 is connected to the upper part of the right end of the mask main body 10 through ultrasonic adhesion, thermal adhesion, adhesive (such as hot melt adhesive), etc. The other end of the detachable part 51 on the ear side is connected to the lower part of the right end of the mask main body 10 through ultrasonic bonding, thermal bonding, adhesive, etc.

(Structure-Ear Side Detachable Part-Second Ear Side Detachable Part) The second ear side detachable part 52 is for detachably attaching the mask main body 10 to the wearer's left ear. The second ear side attaching and detaching part 52 is made of, for example, a known wire for ear hooks (for example, a polyolefin-made substantially loop-shaped wire having a length that can be hung on the left ear) and is provided at the left end of the mask main body 10 . Specifically, as shown in FIG. 1 , one end of the second ear side detachable portion 52 is connected to the upper part of the left end of the mask main body 10 through ultrasonic adhesion, thermal adhesion, adhesive, etc., while the second ear side detachable portion 52 The other end of the mask body 10 is connected with the lower part of the left end of the mask main body 10 through ultrasonic bonding, thermal bonding, adhesive, etc.

By using the above-mentioned mask 1, the product quality of the mask main body 10 can be ensured through the product quality of the antiviral base material 20, and the manufacturability of the mask 1 can be improved.

(Method of Manufacturing Mask) Next, a method of manufacturing the mask 1 will be described.

The method for making the mask 1 according to the embodiment includes a first forming step, a second forming step and an assembling step.

(Method of Manufacturing Mask - First Forming Step) First, the first forming step will be described. The first forming step is a step of forming the antiviral layer 22 on the first base material 21 .

Specifically, firstly, while the roll-shaped first base material 21 is unrolled by a known unwinder, a coating liquid is applied to the unrolled first base material 21 by a known coating device (for example, a gravure coater). 12 on the outside of the mask. Then, the coated first base material 21 is dried for a predetermined time by a known drying device (for example, hot air drying device), so as to form the antiviral layer 22 . Subsequently, the first base material 21 on which the antiviral layer 22 is formed is cut into a predetermined size by a known cutting machine.

Here, the term "coating liquid" refers to a liquid for applying the tea leaf extract material on the first base material 21, and is configured to contain, for example, the tea leaf extract material, water, ethanol, isopropanol, and the like.

In addition, the coating amount of the coating liquid on the first base material 21 is arbitrary; however, according to the embodiment, the coating amount of the tea extract material is set to 0.2 g/m ² , and may be set such as, for example, coating of the coating liquid Amount = about 0.8 g/m ² .

(Method of Manufacturing Mask—Second Forming Step) Next, the second forming step will be described. The second forming step is a step of forming the mask main body 10 after the first forming step.

Specifically, first, the outer second base material 23, the inner second base material 24, and the middle second base material 25 are stacked in a stacked form through known processing equipment, and at the same time, the first base material 21 is placed on the outer second base material. material 23 and the intermediate second base material 25 . Next, by using known processing equipment, the outer second base material 23 , inner second base material 24 , middle second base material 25 , and first base material 21 are wrinkled to form the wrinkled portion 30 . Subsequently, using known adhesive equipment, the outer second base material 23 and the middle second base material 25 are connected to each other through ultrasonic bonding or the like, and at the same time, the middle second base material 25 and the inner second base material 24 are connected to each other through ultrasonic bonding or the like. connected, thus forming the mask body 10.

(Method of Manufacturing Mask - Assembly Step) Subsequently, the assembly step will be described. The assembling step is a step of assembling the nose pad portion 40 and the ear side detachable portion 50 on the mask main body 10 after the second forming step.

Specifically, the nose pad 40 is connected to the mask main body 10 (specifically, the outer second base material 23 ) through ultrasonic adhesion or the like by using known assembly equipment, thereby assembling the nose pad 40 to the mask main body 10 . In addition, the ear side detachable part 50 is connected to the mask main body 10 through ultrasonic bonding or the like by using known sewing equipment, so the ear side detachable part 50 is assembled to the mask main body 10 .

Through such a manufacturing method, the mask 1 can be simply manufactured. In addition, in the first forming step, the antiviral layer 22 can be formed by applying the coating liquid on the first base material 21 so that the coating amount of the tea extract material is 0.2 g/m ² , so the mask main body 10 can It has desired antiviral properties and can ensure the product quality of the mask main body 10 .

(Test Results) Next, test results of the first to fifth antiviral property confirmation tests conducted by the applicant of the present invention will be described.

(Test Results - Outline of the First Antiviral Property Confirmation Test) First, an outline of the first antiviral property confirmation test will be described. Here, the "first confirmation test of antiviral properties" is a test for confirming whether each sample has antiviral properties against avian influenza virus.

In addition, the test method of the first antiviral property confirmation test is arbitrary; however, the test method is performed as follows. That is, first, 400 μl of a virus liquid containing avian influenza virus (specifically, a virus liquid adjusted to 10 ^9.5 EID ₅₀ /0.2 ml with PBS (phosphate buffered saline)) was applied to each 0.2 g sample, Then the virus solution was reacted at room temperature for 10 minutes. Next, the reaction solution extracted from each sample was serially diluted 10-fold with antibiotic-containing PBS, and 0.2 ml of each diluted solution was inoculated into fertilized egg allantoic chorion, followed by virus culture for 2 days. Subsequently, the allantoic fluid was collected from the allantoic chorion of each fertilized egg, and the virus proliferation status in the collected allantoic fluid was detected by using the HA test. Then, the test results were calculated as virus potency (log ₁₀ EID ₅₀ /0.2 ml) (by the way, in FIG. 3 , the average value of virus potency calculated based on multiple test results is shown).

In addition, the samples used for the first confirmation test of antiviral properties were divided into sample A1 to sample A5.

Here, sample A1 is a tea-scented paper having tea residues added thereto (specifically, a tea-scented paper with 20% tea residues added to pulp paper). In addition, sample A2 is a sample in which the antiviral layer 22 (specifically, the antiviral layer 22 in which the coating amount of the tea extract is 0.1 g/m ² ) was formed on the above-mentioned tea-scented paper. In addition, sample A3 is a sample in which the antiviral layer 22 (specifically, the antiviral layer 22 in which the coating amount of the tea extract material is 0.2 g/m ² ) is formed on the above-mentioned tea-flavored paper. In addition, sample A4 is a tea-scented paper having tea residue added thereto (specifically, a tea-scented paper having 60% of tea residue in a paper material). In addition, sample A5 is pure pulp paper.

(Test Results - Details of the First Antiviral Property Confirmation Test) Next, details of the test results of the first antiviral property confirmation test will be described.

As shown in FIG. 3 , regarding the virus potency, it was confirmed that the virus potency of samples A1 to A4 was lower than that of sample A5. In particular, it was confirmed that the virus potency of sample A2 and sample A3 was lower than that of sample A1 and sample A5.

In addition, with regard to the antiviral activity value (the value used to determine the presence or absence of antiviral properties, which is obtained by subtracting the virus potency of sample A5 from the virus potency of each sample), it was confirmed that sample A1 and The antiviral activity value of sample A4 did not meet the standard value (≧2.0 (the standard value defined by ISO 18184) (Figure 3, indicated by "╳"); however, the antiviral activity values of sample A2 and sample A3 both met Standard value (indicated by "○" in FIG. 3). Therefore, it was verified that sample A1 and sample A4 did not have desired antiviral properties, and it was verified that sample A2 and sample A3 had desired antiviral properties.

In addition, regarding the corrected antiviral activity value (the value used to determine the presence or absence of antiviral properties, this value is obtained by subtracting the antiviral activity value of sample A1 from the antiviral activity value of sample A2 or sample A3 obtained), it was confirmed that the corrected antiviral activity values of sample A2 and sample A3 conformed to the above-mentioned standard value (indicated by "(○)" in FIG. 3 ). In particular, it was also confirmed that the corrected antiviral activity value of sample A3 conformed to the standard value, indicating higher antiviral activity than that defined in ISO 18184 (≧3.0; hereinafter, referred to as "higher standard value"). Therefore, it was confirmed that the antiviral layer 22 of Sample A2 and Sample A3 had desired antiviral properties.

From the above results, the effectiveness of setting the coating amount of the tea extract material in the antiviral layer 22 to 0.1 g/m ² or more was confirmed. In addition, the effectiveness of combining the antiviral layer 22 with the first base material 21 to form a tea-scented paper was also confirmed.

(Test Results - Outline of Second Antiviral Property Confirmation Test) Next, an outline of the second antiviral property confirmation test will be described. Here, the "second antiviral property confirmation test" is a test for confirming whether each sample has antiviral property against coronavirus (delta variant).

In addition, the test method of the second antiviral property confirmation test is arbitrary; however, the test method is performed as follows. That is, the host cells are infected with coronavirus, EMEM is added to the cells, the cells are cultured for a predetermined time, and then the supernatant obtained by centrifuging the culture medium at 4°C and 1000xg for 15 minutes with a centrifuge device is used as a virus suspension. Next, the virus suspension was diluted 10 times with sterilized distilled water, adjusted to 1 to 5×10 ⁷ PFU/ml, and the resultant was used as a test virus suspension. Next, 0.2 ml of the test virus suspension was inoculated into each 0.4 g sample. Next, each sample was allowed to act at 25° C. for 2 hours, and then each sample to which 20 ml of the rinsing liquid was added was stirred with a chamber mixer. Subsequently, the coronavirus was washed out from each sample after stirring, and then the virus titer was assigned by plaque assay (By the way, in Fig. 4, the virus potency calculated based on the results of multiple detection average value).

In addition, the samples used for the second confirmation test of antiviral properties are divided into sample B1 and sample B2.

Here, sample B1 is pure pulp paper. In addition, sample B2 is a sample in which the antiviral layer 22 (specifically, the antiviral layer 22 in which the coating amount of the tea extract material is 0.2 g/m ² ) was formed on pure pulp paper.

(Test Results - Details of Second Antiviral Property Confirmation Test) Next, details of test results of the second antiviral property confirmation test will be described.

As shown in FIG. 4 , regarding the virus potency, it was confirmed that the virus potency of the sample B2 was lower than that of the sample B1.

In addition, with regard to the antiviral activity value (the value used to determine the presence or absence of antiviral properties, which is obtained by subtracting the virus potency of sample B1 from the virus potency of each sample), it was confirmed that the sample B2 The antiviral activity value satisfied the above-mentioned standard value (in FIG. 4, indicated by "◯"), and it was confirmed that the antiviral activity value also satisfied the above-mentioned higher standard value. Therefore, it was confirmed that Sample B2 had the desired antiviral properties.

From the above results, the effectiveness of setting the coating amount of the tea extract material in the antiviral layer 22 to 0.2 g/m ² was confirmed.

(Test Results - Outline of the Third Antiviral Property Confirmation Test) Next, an outline of the third antiviral property confirmation test will be described. Here, the "third antiviral property confirmation test" is a test for confirming whether each sample has antiviral property against influenza virus (type A).

In addition, the test method of the third antiviral property confirmation test is arbitrary; however, the test method is performed as follows. That is, first, 400 mg of each sample and 0.2 ml of an influenza virus solution prepared in water containing 10% Eagle's medium were contained in a centrifuge tube, and allowed to stand at 37°C and 5% CO ₂ for 2 hours. Next, the influenza virus solution was extracted from the centrifuge tube using 20 ml of SCDLP medium, and the extracted influenza virus solution was used to produce a ten-fold serial dilution system. Next, 1 ml of ten-fold serial dilution system was dropped on the host cells, and the infection treatment was carried out at 37°C and 5% CO ₂ for 1 hour. Next, replace the supernatant of the infected cells with 0.8% oxoid agar solution, and culture the cells at 37°C and 5% CO ₂ for 1 to 2 days. Next, plaque formation was confirmed by visual inspection, and the cultured products were fixed with 5% glutaraldehyde solution and stained with methylene blue. Then, virus potency was assigned based on the measurement data of the number of plaques thus formed.

In addition, the samples used for the third confirmation test of antiviral properties were divided into samples C1 to C3.

Here, sample C1 is a tea-scented paper (specifically, a tea-scented paper in which 20% of tea residue was added to pulp paper). In addition, sample C2 is a sample in which the antiviral layer 22 (specifically, the antiviral layer 22 in which the coating amount of the tea extract material is 0.2 g/m ² ) was formed on pure pulp paper. In addition, sample C3 is a sample in which the antiviral layer 22 (specifically, the antiviral layer 22 in which the coating amount of the tea extract material is 0.2 g/m ² ) was formed on a simple nonwoven fabric material.

(Test Results - Details of the Third Antiviral Property Confirmation Test) Next, details of the test results of the third antiviral property confirmation test will be described.

As shown in FIG. 5 , regarding the virus potency, it was confirmed that the virus potency of the samples C2 and C3 was lower than that of the sample C1.

In addition, with regard to the antiviral activity value (the value used to determine the presence or absence of antiviral properties, which is obtained by subtracting the virus potency of sample C1 from the virus potency of each sample), it was confirmed that samples C2 and The antiviral activity value of sample C3 met the above-mentioned standard value (indicated by "◯" in FIG. 5 ). Therefore, it was confirmed that sample C2 and sample C3 have desired antiviral properties.

From the above results, the effectiveness of setting the coating amount of the tea extract in the antiviral layer 22 to 0.2 g/m ² was confirmed.

(Test Results - Outline of the Fourth Antiviral Property Confirmation Test) Next, an outline of the fourth antiviral property confirmation test will be described. Here, the "fourth antiviral property confirmation test" is similar to the second antiviral property confirmation test, and is a test for confirming whether each sample has antiviral property against coronavirus (delta variant).

In addition, the test method of the fourth antiviral property confirmation test is arbitrary; however, the test method is similar to the test method of the second antiviral property confirmation test.

In addition, the samples used for the fourth validation test of anti-virus properties are divided into sample D1 and sample D2.

Here, sample D1 is pure pulp paper. In addition, sample D2 is a sample in which the antiviral layer 22 (specifically, the antiviral layer 22 in which the coating amount of the tea extract material is 0.4 g/m ² ) was formed on pure pulp paper.

(Test Results - Details of the Fourth Antiviral Property Confirmation Test) Next, details of the test results of the fourth antiviral property confirmation test will be described.

As shown in FIG. 6 , regarding the virus potency, it was confirmed that the virus potency of the sample D2 was lower than that of the sample D1.

In addition, with regard to the antiviral activity value (the value used to determine the presence or absence of antiviral properties, which is obtained by subtracting the virus potency of sample D1 from the virus potency of each sample), it was confirmed that the sample D2 The antiviral activity value met the above-mentioned standard value (indicated by "○" in Fig. 6), and it was confirmed that the antiviral activity value also met the above-mentioned higher standard value. Therefore, it was confirmed that the sample D2 had the desired antiviral properties.

From the above results, the effectiveness of setting the coating amount of the tea extract material in the antiviral layer 22 to 0.4 g/m ² was confirmed.

(Test Results - Outline of Fifth Antiviral Property Confirmation Test) Subsequently, an outline of the fifth antiviral property confirmation test will be described. Here, the "fifth antiviral property confirmation test" is a test for confirming whether each sample has antiviral property against coronavirus (omicron variant).

In addition, the test method of the fifth antiviral property confirmation test is arbitrary; however, the test method is similar to the test method of the second antiviral property confirmation test.

In addition, the samples used for the fifth validation test of antiviral properties are divided into sample E1 and sample E2.

Here, sample E1 is pure pulp paper. In addition, sample E2 is a sample in which the antiviral layer 22 (specifically, the antiviral layer 22 in which the coating amount of the tea extract material is 0.2 g/m ² ) was formed on pure pulp paper.

(Test Results - Details of Fifth Antiviral Property Confirmation Test) Next, details of test results of the fifth antiviral property confirmation test will be described.

As shown in FIG. 7 , regarding the virus potency, it was confirmed that the virus potency of the sample E2 was lower than that of the sample E1.

In addition, with regard to the antiviral activity value (the value used to determine the presence or absence of antiviral properties, which is obtained by subtracting the virus potency of sample E1 from the virus potency of each sample), it was confirmed that the sample E2 The antiviral activity value met the above-mentioned standard value (indicated by "○" in Fig. 7), and it was confirmed that the antiviral activity value also met the above-mentioned higher standard value. Therefore, it was confirmed that the sample E2 had the desired antiviral properties.

From the above results, the effectiveness of setting the coating amount of the tea extract material in the antiviral layer 22 to 0.2 g/m ² was confirmed.

(Effect) According to such an embodiment, since the antiviral base material 20 contains the antiviral layer 22 formed by applying the tea extract material extracted from tea leaves on the first base material 21, and the tea extract material has an antiviral effect. The coating amount in layer 22 is set to 0.1 g/m ^More than, can make antiviral base material 20 have desired antiviral property, and can guarantee the product quality of antiviral property base material 20 (specifically, based on antiviral property Product quality of viral properties).

In addition, since the coating amount of the tea extract material in the antiviral layer 22 is set to be more than 0.2 g/m ² , the antiviral basic material 20 can have higher antiviral properties, and can further ensure the product quality of the antiviral basic material .

In addition, since the tea leaf extract material contains catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, the yellow Theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate and theaflavin-3,3'-digallate, antiviral basis The material 20 can reliably have desired antiviral properties, and the product quality of the antiviral base material 20 can be easily ensured.

In addition, since a plurality of second base materials are provided in a laminated form, and the first base material 21 is disposed between the second base materials so that the first base material 21 is not exposed to the outside, it is possible to prevent the first base material 21 from being exposed to Externally, the deterioration of the design performance of the anti-virus base material 20 caused by the first base material 21 can be prevented, and the protective performance of the first base material can be improved.

In addition, among the plurality of second base materials, the mesh size of at least any one of the second base materials located on one side of the stacking direction relative to the first base material 21 is set to be smaller than that of the second base material located on the other side of the stacking direction relative to the first base material 21 . Compared with the case where the mesh size of the plurality of second base materials is the same, the mesh size of the second base material on the side makes it difficult for foreign matters and/or viruses to pass through, thus improving the filtering function.

In addition, since the mask 1 includes the mask body 10 formed by the antiviral base material 20, the product quality of the mask body 10 can be ensured through the product quality of the antivirus base material 20, and the manufacturability of the mask 1 can be improved.

[III] Modification example of the embodiment: So far, the embodiment of the present invention has been described; however, the specific structure and components of the present invention can be arbitrarily modified and improved within the scope of the technical idea of each invention described in the claims. Hereinafter, such modification examples will be described.

(About the technical problems and beneficial effects of the present invention) First, the technical problems and beneficial effects to be solved by the present invention are not limited to the above content, and the present invention can also solve the above-mentioned undescribed problems or provide the above-mentioned undescribed effects. Also, only a part of the described problems may be solved, or only a part of the described effects may be provided.

(About shape, numerical value, structure, and time series) Regarding the constituent elements listed as examples of embodiments and drawings, and the mutual relationship between the shape, numerical value, or structure or time series of plural constituent elements, it can be found in this Modifications and improvements can be made arbitrarily within the scope of the technical idea of the invention.

(Application object of antiviral base material) In the above-mentioned embodiments, the case where the antiviral base material 20 is applied to the mask 1 (specifically, the mask main body 10) has been described; The viral base material 20 can also be applied to paper and/or fabric products other than the mask 1 . In this case, the first base material 21 and/or the second base material may be made of paper materials (examples include paper materials for packaging, paper materials for printing, paper materials for cushioning materials, and paper materials for paper containers). paper materials) and/or fabric materials (examples include woven materials, non-woven materials and knitted materials).

(About the mask) In the above-mentioned embodiment, the mask 1 has been described to include the folded portion 30 and the nose pad 40; however, it is not limited thereto, for example, the folded portion 30 and/or the nose pad 40 may be omitted.

(About the anti-virus base material) In the above-mentioned embodiment, it is explained that the anti-virus base material 20 includes a plurality of second base materials (the outer second base material 23, the inner second base material 24 and the middle second base material 25); However, the present invention is not limited thereto. For example, the antiviral base material 20 may contain another second base material in addition to the plurality of second base materials. Alternatively, at least one of the plurality of second base materials may be omitted. For example, the middle second base material 25 may be omitted, or the outer second base material 23 , the inner second base material 24 , and the middle second base material 25 may be omitted.

(Regarding the first base material) In the above-mentioned embodiments, the case where the first base material 21 is disposed between the second base materials so that the first base material 21 is not exposed to the outside has been described; however, the present invention is not limited thereto . For example, the first base material 21 may be provided to be exposed to the outside.

(Regarding the antiviral layer) In the above-mentioned embodiment, it was explained that the antiviral layer 22 is formed by applying the tea leaf extract material on substantially the whole of the first base material 21; however, it is not limited thereto, for example, antiviral The layer 22 may be formed by applying the tea leaf extract material on only a portion of the first base material 21 (eg, a portion other than the end of the first base material 21 ).

(Regarding the second base material) In the above-mentioned embodiment, it was explained that among the plurality of second base materials, the mesh size of the second base material 25 located in the middle of the stacking direction relative to the first base material 21 is set to be smaller than The mesh size of the second base material 23 located on the other side of the stacking direction with respect to the first base material 21; however, the present invention is not limited thereto. For example, the mesh sizes of the inner second base material 24 and the middle second base material 25 on one side in the stacking direction relative to the first base material 21 are set to be smaller than the mesh size of the outer second base material 23 . Alternatively, the mesh sizes of the plurality of second base materials may all be set to be approximately the same.

(Note) The antiviral base material in Note 1 is an antiviral base material having antiviral properties, and the antiviral base material includes: a first base material composed of a paper material or a fabric material; The antiviral layer formed by the tea extract material extracted from the tea leaves, wherein the coating amount of the tea extract material in the antiviral layer is set at 0.1 g/ ^m2 or more.

The antiviral base material according to Note 2 of the antiviral base material in Note 1, wherein the coating amount of the tea extract material in the antiviral layer is set to 0.2 g/m ² or more.

The antiviral basic material according to Note 3 of the antiviral basic material of Note 1 or Note 2, wherein the tea extract material contains catechin, epicatechin, epigallocatechin, epicatechin gall Ester, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate and tea Flavin-3,3'-Digallate.

The antiviral base material according to Note 4 of the antiviral base material of Note 1 or Note 2, wherein the antiviral base material comprises a plurality of second base materials composed of paper materials and/or fabric materials, and the plurality of second base materials The material is not provided with an antiviral layer, a plurality of second base materials are provided in a laminated form, and the first base material is provided between the second base materials so that the first base materials are not exposed to the outside.

The antiviral base material according to Note 5 of the antiviral base material of Note 4, wherein among the plurality of second base materials, at least any one of the second base materials located on one side of the stacking direction relative to the first base material is sieved The pore size is set to be smaller than the mesh size of the second base material located on the other side in the stacking direction with respect to the first base material.

The mask of note 6 is a mask that contains a mask body formed of the antiviral base material according to any one of notes 1 to 5.

(Beneficial Effect of Note) According to the antiviral base material of Note 1, since the antiviral base material includes an antiviral layer formed by applying a tea extract material extracted from tea leaves on the first base material, and the tea extract material The coating amount in the antiviral layer is set to 0.1 g/ ^m2 or more, which can make the antiviral base material have the desired antiviral properties, and can ensure the product quality of the antiviral base material (specifically, based on the antiviral properties product quality).

According to the antiviral base material in Note 2, since the coating amount of the tea extract material in the antiviral layer is set to be 0.2 g/m2 or ^more , the antiviral base material can have high antiviral properties and further secure the antiviral foundation The product quality of the material.

According to the antiviral basic material in Note 3, since the tea extract material contains catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate Gallate, Theaflavin, Theaflavin-3-O-gallate, Theaflavin-3'-O-gallate and Theaflavin-3,3'-Digallate The antiviral basic material 20 can reliably have the desired antiviral performance, and can easily ensure the product quality of the antiviral basic material.

According to the antiviral base material of Note 4, since a plurality of second base materials are arranged in a layered form, and the first base material is arranged between the second base materials, so that the first base material is not exposed to the outside, the second base material can be avoided. The exposure of a base material to the outside can prevent the degradation of the design performance of the anti-virus base material caused by the first base material, and can improve the protective performance of the first base material.

According to the antiviral base material of Note 5, among the plurality of second base materials, the mesh size of at least any one of the second base materials located on one side of the stacking direction relative to the first base material is set to be smaller than that of the first base material. The mesh size of the second base material on the other side of the base material in the stacking direction is more difficult for foreign substances and/or viruses to pass through than the case where the mesh size of a plurality of second base materials is the same, thereby improving filtration. Function.

According to the mask in Note 6, since the mask includes a mask body formed of the antiviral basic material described in any one of Notes 1 to 5, the product quality of the mask body can be ensured through the product quality of the antiviral basic material, And can enhance the manufacturability of masks.

1: mask 10: The main body of the mask 11: Inside the mask 12: Outside the mask 20: Antiviral basic materials 21: First base material 22: Anti-virus layer 23: Outer second base material 24: The inner second base material 25: Intermediate second basic material 30: folds 40: nose pad 50: Ear side loading and unloading part 51: The loading and unloading part on the first ear side 52: Second ear side loading and unloading part

Fig. 1 is a diagram conceptually illustrating a mask according to an embodiment of the present invention, Fig. 1(a) is a perspective view, and Fig. 1(b) is an exploded perspective view of Fig. 1(a). Fig. 2 is a diagram illustrating the first base material, Fig. 2(a) is a front view, Fig. 2(b) is a rear view, and Fig. 2(c) is a top view. Fig. 3 is a graph showing test results of the first antiviral property validation test. Fig. 4 is a graph showing the test results of the second antiviral property validation test. Fig. 5 is a graph showing the test results of the third antiviral property validation test. Fig. 6 is a graph showing test results of the fourth antiviral property validation test. Fig. 7 is a graph showing the test results of the fifth antiviral property validation test.

1: mask

10: The main body of the mask

12: Outside the mask

20: Antiviral basic materials

21: First base material

22: Anti-virus layer

23: Outer second base material

24: The inner second base material

25: Intermediate second basic material

30: folds

40: nose pad

50: Ear side loading and unloading part

51: The loading and unloading part on the first ear side

52: Second ear side loading and unloading part

Claims (6)

An antiviral basic material, the antiviral basic material has antiviral properties, the antiviral basic material includes: a first basic material, which is made of paper material or fabric material; and an antiviral layer, which is obtained by extracting tea leaves A tea extract material is applied on the first base material, wherein the coating amount of the tea extract material in the antiviral layer is above 0.1 g/m ² . The antiviral basic material according to claim 1, wherein the coating amount of the tea extract material in the antiviral layer is 0.2 g/m ² or more. The antiviral basic material as described in Claim 1 or 2, Wherein the tea extract material includes catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin , Theaflavin-3-O-gallate, Theaflavin-3'-O-gallate and Theaflavin-3,3'-Digallate. The antiviral basic material as described in Claim 1 or 2, Wherein the antiviral base material includes a plurality of second base materials made of paper materials and/or fabric materials, and the plurality of second base materials are not provided with the antiviral layer, the plurality of second base materials are arranged in a stacked form, and The first base material is disposed between the second base materials such that the first base material is not exposed to the outside. The antiviral basic material as described in Claim 4, Among the plurality of second base materials, the mesh size of at least any one of the second base materials located on one side of the stacking direction relative to the first base material is set to be smaller than that located on the side relative to the first base material. The mesh size of the second base material on the other side of the stacking direction. A mask comprising: A mask main body formed from the antiviral basic material as described in Claim 1 or 2.

Images